Please use this identifier to cite or link to this item: doi:10.22028/D291-33593
Title: Hepatic steatosis in patients with acromegaly
Author(s): Koutsou-Tassopoulou, Andreani
Papapostoli-Sklavounou, Ifigeneia
Krawczyk, Marcin
Friesenhahn-Ochs, Bettina
Weber, Susanne N.
Lammert, Frank
Stokes, Caroline S.
Language: English
Title: Endocrinology, Diabetes & Metabolism
Volume: 2
Issue: 4
Publisher/Platform: Wiley
Year of Publication: 2019
Free key words: adiponutrin
controlled attenuation parameter
MBOAT7
nonalcoholic fatty liver disease
TM6SF2
transient elastography
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Objective Comorbid NAFLD is increasingly being diagnosed in patients with diabetes and nondiabetic endocrinopathies. The aim of this study was to assess hepatic steatosis noninvasively by transient elastography in patients with acromegaly. Design A cross‐sectional study including 22 patients with acromegaly. Methods Hepatic steatosis was quantified using controlled attenuation parameter (CAP) during elastography. Anthropometric measurements were obtained, serum liver function tests and lipid and hormone profiles were measured, and prosteatogenic gene variants were genotyped using standard assays. Results In total, 41% of patients were women (mean age 60 ± 14.7 years, mean BMI 31.2 ± 4.6 kg/m2). Hepatic steatosis, as defined by CAP > 248 dB/m, was present in 66% of patients. Five (45%) of the patients with hepatic steatosis also had fibrosis, and one presented with cirrhosis. Nine patients were carriers of the PNPLA3 p.I148M prosteatogenic [M] risk allele, eight of whom were heterozygotes. CAP values were significantly (P = .045) higher in these patients and corresponded to advanced steatosis, as compared to patients with the wild‐type genotype, who demonstrated CAP values consistent with mild steatosis (311 ± 33 dB/m. vs 254 ± 62 dB/m). CAP values did not differ significantly in carriers of distinct TM6SF2 and MBOAT7 genotypes; however, carriers of the risk alleles displayed higher CAP as compared to wild‐type patients. Conclusions This study shows that in patients with acromegaly, carriers of the PNPLA3 susceptibility allele are at risk of developing hepatic steatosis, as assessed by CAP. Comorbid NAFLD might compound prognosis in such patients; thus, further research into the pathomechanisms and treatment of NAFLD in acromegaly is warranted.
DOI of the first publication: 10.1002/edm2.90
Link to this record: urn:nbn:de:bsz:291--ds-335933
hdl:20.500.11880/30925
http://dx.doi.org/10.22028/D291-33593
ISSN: 2398-9238
Date of registration: 22-Mar-2021
Faculty: M - Medizinische Fakultät
Department: M - Innere Medizin
Professorship: M - Prof. Dr. Frank Lammert
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
edm2.90.pdf514,5 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons